Veeva Systems Inc. $VEEV Shares Bought by Fiera Capital Corp

Fiera Capital Corp lifted its holdings in Veeva Systems Inc. (NYSE:VEEV) by 2.7% in the second quarter, according to its most recent disclosure with the SEC. The institutional investor owned 357,999 shares of the technology company’s stock after purchasing an additional 9,263 shares during the period. Fiera Capital Corp owned approximately 0.22% of Veeva Systems worth $103,097,000 at the end of the most recent reporting period.

Several other large investors have also recently bought and sold shares of VEEV. Thompson Davis & CO. Inc. purchased a new stake in shares of Veeva Systems in the 2nd quarter valued at about $200,000. ABN Amro Investment Solutions purchased a new position in shares of Veeva Systems during the second quarter worth about $18,086,000. Police & Firemen s Retirement System of New Jersey increased its position in Veeva Systems by 4.5% in the 2nd quarter. Police & Firemen s Retirement System of New Jersey now owns 22,370 shares of the technology company’s stock valued at $6,442,000 after acquiring an additional 972 shares during the period. Geode Capital Management LLC increased its position in Veeva Systems by 3.8% in the 2nd quarter. Geode Capital Management LLC now owns 3,092,539 shares of the technology company’s stock valued at $888,108,000 after acquiring an additional 114,003 shares during the period. Finally, Forsta AP Fonden lifted its position in Veeva Systems by 31.5% during the 2nd quarter. Forsta AP Fonden now owns 40,500 shares of the technology company’s stock worth $11,663,000 after acquiring an additional 9,700 shares during the period. Hedge funds and other institutional investors own 88.20% of the company’s stock.

Insider Activity at Veeva Systems

In related news, SVP Jonathan Faddis sold 720 shares of the business’s stock in a transaction that occurred on Monday, October 6th. The stock was sold at an average price of $298.12, for a total transaction of $214,646.40. Following the transaction, the senior vice president directly owned 7,868 shares of the company’s stock, valued at approximately $2,345,608.16. The trade was a 8.38% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, insider Eleni Nitsa Zuppas sold 6,000 shares of the stock in a transaction that occurred on Tuesday, October 7th. The shares were sold at an average price of $306.62, for a total transaction of $1,839,720.00. Following the completion of the sale, the insider directly owned 25,325 shares of the company’s stock, valued at $7,765,151.50. This trade represents a 19.15% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders have sold 24,665 shares of company stock worth $7,438,000. 10.30% of the stock is currently owned by company insiders.

Veeva Systems Stock Performance

Veeva Systems stock opened at $297.11 on Thursday. The stock has a fifty day moving average of $288.05 and a two-hundred day moving average of $276.78. Veeva Systems Inc. has a fifty-two week low of $201.54 and a fifty-two week high of $310.50. The company has a market capitalization of $48.70 billion, a price-to-earnings ratio of 61.01, a PEG ratio of 2.22 and a beta of 0.98.

Veeva Systems (NYSE:VEEV) last released its earnings results on Wednesday, August 27th. The technology company reported $1.26 earnings per share for the quarter, missing the consensus estimate of $1.90 by ($0.64). Veeva Systems had a return on equity of 13.72% and a net margin of 27.29%.The business had revenue of $789.08 million for the quarter, compared to analysts’ expectations of $768.49 million. During the same quarter last year, the company posted $1.62 earnings per share. The business’s quarterly revenue was up 16.7% compared to the same quarter last year. Veeva Systems has set its Q3 2026 guidance at 1.940-1.950 EPS. FY 2026 guidance at 7.780-7.780 EPS. On average, analysts forecast that Veeva Systems Inc. will post 4.35 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on VEEV shares. Mizuho upped their price target on Veeva Systems from $295.00 to $325.00 and gave the stock an “outperform” rating in a research note on Friday, August 29th. JPMorgan Chase & Co. raised shares of Veeva Systems from a “neutral” rating to an “overweight” rating and boosted their price objective for the company from $290.00 to $330.00 in a research note on Monday, September 8th. William Blair restated an “outperform” rating on shares of Veeva Systems in a research report on Friday, October 17th. Piper Sandler lifted their target price on shares of Veeva Systems from $325.00 to $355.00 and gave the company an “overweight” rating in a report on Thursday, August 28th. Finally, Morgan Stanley boosted their price target on shares of Veeva Systems from $210.00 to $222.00 and gave the stock an “underweight” rating in a research note on Thursday, August 28th. Seventeen equities research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $307.58.

Veeva Systems Company Profile

Veeva Systems Inc provides cloud-based software for the life sciences industry. It offers Veeva Commercial Cloud, a suite of software and analytics solutions, such as Veeva customer relationship management (CRM) that enable customer-facing employees at pharmaceutical and biotechnology companies; Veeva Vault PromoMats, an end-to-end content and digital asset management solution; Veeva Vault Medical that provides source of medical content across multiple channels and geographies; Veeva Crossix, an analytics platform for pharmaceutical brands; Veeva OpenData, a customer reference data solution; Veeva Link, a data application that allows link to generate real-time intelligence; and Veeva Compass includes de-identified and longitudinal patient data for the United States.